Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.

被引：1
|
作者：
Akce, Mehmet
Alese, Olatunji B.
Shaib, Walid Labib
Wu, Christina Sing-Ying
Lesinski, Gregory B.
El-Rayes, Bassel F.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH USA
[3] Richard J Solove Res Inst, Columbus, OH USA
[4] Emory Univ Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.TPS526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS526
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies.
    Anderson, S
    Dizon, D
    Sabbatini, P
    Dupont, J
    Pezzulli, S
    Massey, A
    Aghajanian, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 151S - 151S
  • [22] Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
    Saeed, Anwaar
    Park, Robin
    Dai, Junqiang
    Al Rjabi, Raed
    Kasi, Anup
    Baranda, Joaquin
    Willamson, Stephen
    Saeed, Azhar
    Ripp, Jacob
    Collins, Zachary
    Mulvaney, Kelly
    Shugrue, Molly
    Firth-Braun, Jeanette
    K. Godwin, Andrew
    Madan, Rashna
    Phadnis, Milind
    Sun, Weijing
    CELL REPORTS MEDICINE, 2023, 4 (02)
  • [23] Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
    Chi, Ping
    Qin, Li-Xuan
    Camacho, Niedzica
    Kelly, Ciara M.
    D'Angelo, Sandra P.
    Dickson, Mark A.
    Gounder, Mrinal M.
    Keohan, Mary L.
    Movva, Sujana
    Nacev, Benjamin A.
    Rosenbaum, Evan
    Thornton, Katherine A.
    Crago, Aimee M.
    Francis, Jasmine H.
    Martindale, Moriah
    Phelan, Haley T.
    Biniakewitz, Matthew D.
    Lee, Cindy J.
    Singer, Samuel
    Hwang, Sinchun
    Berger, Michael F.
    Chen, Yu
    Antonescu, Cristina R.
    Tap, William D.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1507 - 1517
  • [24] Phase I trial of gemcitabine and epirubicin in patients with solid malignancies.
    Mahadevan, D
    Dreisbach, L
    Williams, D
    Pilkington, D
    Gebremarium, C
    Martin, E
    Obregon, Y
    Von Hoff, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 360S - 360S
  • [25] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [26] Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies.
    Bustinza-Linares, E.
    Falchook, G. S.
    Fu, S.
    Naing, A.
    Hong, D. S.
    Hu, W.
    Moulder, S. L.
    Wheler, J. J.
    Sood, A.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A phase II trial of modified triple doublets for the treatment of advanced Mullerian malignancies.
    Matulonis, UA
    Campos, S
    Krasner, C
    Duska, L
    Penson, RP
    Falke, R
    Roche, M
    Smith, LM
    Lee, H
    Seiden, MV
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 457S - 457S
  • [28] A phase I trial of the mTOR inhibitor temsirolimus (TEM) in combination with capecitabine (CAP) in patients with advanced malignancies.
    Pishvaian, Michael J.
    Wang, Hongkun
    Hardesty, Rosemarie A.
    Deeken, John F.
    He, Aiwu Ruth
    Subramaniam, Deepa Suresh
    Zhuang, Tingting
    McCarthy, Damian L.
    Melville, Heather
    Albanese, Christopher
    Marshall, John
    Hwang, Jimmy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Phase Ib trial of bryostatin 1 in patients with refractory malignancies
    Grant, S
    Roberts, J
    Poplin, E
    Tombes, MB
    Kyle, B
    Welch, D
    Carr, M
    Bear, HD
    CLINICAL CANCER RESEARCH, 1998, 4 (03) : 611 - 618
  • [30] A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.
    Cohen, E. E.
    Sharma, M.
    Janisch, L. A.
    Stadler, W. M.
    Kang, S. P.
    Fleming, G. F.
    Ratain, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345